Study factors that predict response to first-line blood cancer therapy
Part of Blood & lymphatic clinical trials.
This study looks for factors that may predict how well people with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis respond to first treatments such as hydroxyurea or pegylated interferon. It may help doctors choose better treatments by learning what differences affect outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older) with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis
- You have not been treated before and you are starting first-line treatment using hydroxyurea or pegylated interferon
- You can understand and agree to take part in the study by signing consent
- You are covered by social security (affiliated with it)
- You are not currently taking other cancer treatments that would rule you out, such as ruxolitinib, anagrelide, or pipobroman
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene mutation in people with polycythemia vera (PV) or essential thrombocythemia (ET) to understand how it may relate to blood clots. It mainly involves collecting blood samples and joining a medical registry, before clot-lowering medicines start.
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
This study looks at certain markers in the blood to see if they can predict blood clots in people with myeloproliferative neoplasms (MPN) like polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. It is only for people who have a specific JAK2 mutation and are at high risk for clots, and who are already enrolled in another trial and a biobank.
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
This study tests whether doctors can diagnose myeloproliferative neoplasms (slow-growing blood cancers like polycythemia vera, essential thrombocythemia, or myelofibrosis) using a simple blood test instead of a painful bone marrow biopsy. If successful, patients could get diagnosed faster and more comfortably.
This research study looks for specific immune system clues in patients with myeloproliferative neoplasms—rare blood disorders where your bone marrow produces too many blood cells. By identifying these markers, researchers hope to better understand and eventually treat these conditions.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.